{
    "id": "5c73ad377c78d6947100009a",
    "question": "Does Panitumumab prolong survival of biliary tract cancer patients?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the available information about panitumumab and its use in biliary tract cancer patients. Panitumumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), and it has been shown to be effective in treating certain types of cancer, such as colorectal cancer. However, there is limited information available about its use in biliary tract cancer patients. Let\\u2019s review the relevant documents to see if we can find any information about panitumumab in biliary tract cancer patients.\\n\\nDocument [0] does not mention biliary tract cancer, Document [1] mentions EGFR in colorectal cancer, Document [5] mentions panitumumab in metastatic colorectal carcinoma, Document [6] mentions chemotherapy for pancreatic cancer, Document [10] mentions chemotherapy for colorectal cancer, Document [12] mentions bevacizumab in colorectal cancer, Document [14] mentions panitumumab in metastatic colorectal cancer, Document [16] mentions chemotherapy for colorectal cancer, and Document [20] mentions ramucirumab in gastric cancer.\\n\\nHowever, Document [22] mentions that some case series have shown safety and some responses for hepatic arterial chemotherapy with gemcitabine, drug-eluting beads, and 90Yttrium microspheres in biliary tract cancer, but no convincing clinical trials are available.\\n\\nBased on this information, we cannot conclude that panitumumab prolongs survival in biliary tract cancer patients. The available evidence is limited and inconclusive.\\n\\nHowever, it is worth noting that Document [25] mentions that trastuzumab, a different monoclonal antibody, has been shown to be effective in certain types of cancer, such as HER2-positive breast cancer. This suggests that monoclonal antibodies may be effective in certain types of cancer, but this does not necessarily imply that panitumumab will be effective in biliary tract cancer patients.\\n\\nTherefore, the correct answer is:\\n\\nB. no\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_6952",
            "title": "InternalMed_Harrison",
            "content": "benefit. However, preliminary results utilizing another antiangiogenic compound\u2014ramucirumab (Cyranza)\u2014in the treatment of gastric cancer are encouraging. The use of adjuvant chemotherapy alone following the complete resection of a gastric cancer has only minimally improved survival. However, combination chemotherapy administered before and after surgery (perioperative treatment) as well as postoperative chemotherapy combined with radiation therapy reduces the recurrence rate and prolongs survival."
        },
        {
            "id": "Pharmacology_Katzung_5975",
            "title": "Pharmacology_Katzung",
            "content": "Cetuximab, Panitumumab, & Necitumumab The epidermal growth factor receptor (EGFR) is a member of the erb-B family of growth factor receptors, and it is overexpressed in a number of solid tumors, including colorectal cancer, head and neck cancer, NSCLC, and pancreatic cancer. Activation of the EGFR signaling pathway results in downstream activation of several key cellular events involved in cellular growth and proliferation, invasion and metastasis, and angiogenesis. In addition, this pathway inhibits the cytotoxic activity of various anti-cancer agents and radiation therapy, presumably through suppression of key apoptotic mechanisms, thereby leading to the development of cellular drug resistance."
        },
        {
            "id": "InternalMed_Harrison_7034",
            "title": "InternalMed_Harrison",
            "content": "Monoclonal antibodies are also effective in patients with advanced colorectal cancer. Cetuximab (Erbitux) and panitumumab (Vectibix) are directed against the epidermal growth factor recep-543 tor (EGFR), a transmembrane glycoprotein involved in signaling pathways affecting growth and proliferation of tumor cells. Both cetuximab and panitumumab, when given alone, have been shown to benefit a small proportion of previously treated patients, and cetuximab appears to have therapeutic synergy with such chemotherapeutic agents as irinotecan, even in patients previously resistant to this drug; this suggests that cetuximab can reverse cellular resistance to cytotoxic chemotherapy. The antibodies are not effective in the approximate 40% subset of colon tumors that contain mutated K-ras. The use of both cetuximab and panitumumab can lead to an acne-like rash, with the development and severity of the rash being correlated with the likelihood of antitumor efficacy. Inhibitors of the EGFR tyrosine"
        },
        {
            "id": "InternalMed_Harrison_7166",
            "title": "InternalMed_Harrison",
            "content": "showed an improvement in response rate and progression-free survival over single-agent gemcitabine, but no overall survival benefit. However, pooling of two other randomized controlled trials with this trial in a meta-analysis resulted in a survival advantage with GEM-CAP. Addition of erlotinib, a small-molecule epidermal growth factor receptor inhibitor, produced a statistically significant but clinically marginal benefit when added to gemcitabine in the advanced disease setting. A phase III trial limited to good performance status patients with metastatic pancreatic cancer showed improved survival with the combination of 5-FU/FA, irinotecan, and oxaliplatin (FOLFIRINOX) compared with gemcitabine, but with increased toxicity (Table 112-2)."
        },
        {
            "id": "InternalMed_Harrison_407",
            "title": "InternalMed_Harrison",
            "content": "in remarkable antitumor efficacy. Similarly, the anti\u2013epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab appear especially effective in colon cancers in which K-ras, a G protein in the EGFR pathway, is not mutated. Vemurafenib does not inhibit wild-type BRAF but is active against the V600E mutant form of the kinase."
        },
        {
            "id": "Pharmacology_Katzung_6167",
            "title": "Pharmacology_Katzung",
            "content": "Panitumumab is a fully human IgG2 kappa light chain monoclonal antibody. It is approved for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab binds to EGFR (similar to cetuximab), inhibiting epidermal growth factor from binding to its receptor, and prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases. It inhibits cell growth, induces apoptosis, decreases vascular growth factor production, and suppresses internalization of the EGFR. Although dermatologic and infusion-related toxicities are common following infusion of panitumumab, the distinct advantage over cetuximab is that it is fully human (ie, does not elicit HAMAs) and thus has an extended half-life in circulation. This is the first FDA-approved monoclonal antibody produced from transgenic mice expressing the human immunoglobulin gene"
        },
        {
            "id": "InternalMed_Harrison_7163",
            "title": "InternalMed_Harrison",
            "content": "Approximately 30% of patients present with locally advanced, unresectable, but nonmetastatic pancreatic carcinoma. The median survival with gemcitabine is 9 months. Patients who respond to chemotherapy or who achieve stable disease after 3\u20136 months of gemcitabine have frequently been offered consolidation radiotherapy. However, a large, phase III, randomized controlled trial, LAP-07, did not demonstrate any improvement in survival for patients treated with CRT after 4 months of disease control on either gemcitabine or a gemcitabine/erlotinib combination. Approximately 60% of patients with pancreatic cancer present with metastatic disease. Patients with poor performance status do not usually benefit from chemotherapy. Gemcitabine was the standard"
        },
        {
            "id": "InternalMed_Harrison_6405",
            "title": "InternalMed_Harrison",
            "content": "EGF receptor (EGFR)-directed antibodies (such as cetuximab and panitumumab) have activity in colorectal cancer refractory to chemotherapy, particularly when used to augment the activity of an additional chemotherapy program, and in the primary treatment of head and neck cancers treated with radiation therapy. The mechanism of action is unclear. Direct effects on the tumor may mediate an antiproliferative effect as well as stimulate the participation of host mechanisms involving immune cell or complement-mediated response to tumor cell\u2013bound antibody. Alternatively, the antibody may alter the release of paracrine factors promoting tumor cell survival."
        },
        {
            "id": "InternalMed_Harrison_7130",
            "title": "InternalMed_Harrison",
            "content": "far. Several case series have shown safety and some responses for hepatic arterial chemotherapy with gemcitabine, drug-eluting beads, and 90Yttrium microspheres, but no convincing clinical trials are available. Clinical trials are under way with targeted therapies. Bevacizumab plus erlotinib gave a 10% partial response rate with median overall survival of 9.9 months. A sorafenib trial yielded an overall survival of 4.4 months, but 50% of the patients had received previous chemotherapy. Patients with unresectable tumors should be treated in clinical trials."
        },
        {
            "id": "InternalMed_Harrison_7159",
            "title": "InternalMed_Harrison",
            "content": "Patients should have surgery in dedicated pancreatic centers that have lower postoperative morbidity and mortality rates. The standard surgical procedure for patients with tumors of the pancreatic head or uncinate process is a pylorus-preserving pancreaticoduodenectomy (modified Whipple\u2019s procedure). The procedure of choice for tumors of the pancreatic body and tail is a distal pancreatectomy, which routinely includes splenectomy. Postoperative treatment improves long-term outcomes in this group of patients. Adjuvant chemotherapy comprising six cycles of gemcitabine is common practice worldwide based on data from three randomized controlled trials (Table 112-1). The Charit\u00e9 FIGURE 112-3 Staging of pancreatic cancer, and survival according to stage. AJCC, American Joint Committee on Cancer. (Illustration by Stephen Millward.) Survival Study Comparator Arm No. of Patients PFS/DFS (months) Median Survival (months)"
        },
        {
            "id": "InternalMed_Harrison_6804",
            "title": "InternalMed_Harrison",
            "content": "Abbreviations: ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; ILCP, Italian Lung Cancer Project; SWOG, Southwest Oncology Group; FACS, Follow-up After Colorectal Surgery; iPASS, Iressa Pan-Asian Study. one of the targets of pemetrexed, between tumor types. Squamous cancers have a much higher expression of TS compared to adenocarcinomas, accounting for their lower responsiveness to pemetrexed. By contrast, the activity of gemcitabine is not impacted by the levels of TS. Bevacizumab, a monoclonal antibody against VEGF, has been shown to improve response rate, progression-free survival, and overall survival in patients with advanced disease when combined with chemotherapy (see below). However, bevacizumab cannot be given to patients with squamous cell histology NSCLC because of their tendency to experience serious hemorrhagic effects."
        },
        {
            "id": "Pharmacology_Katzung_6031",
            "title": "Pharmacology_Katzung",
            "content": "second-line setting. In patients with early-stage pancreatic cancer who have undergone successful surgical resection, adjuvant chemotherapy with either single-agent gemcitabine or 5-FU/leucovorin is recommended."
        },
        {
            "id": "Pharmacology_Katzung_6027",
            "title": "Pharmacology_Katzung",
            "content": "main foundation of cytotoxic chemotherapy regimens. Recent clinical studies have shown that in tumors with wild-type KRAS and NRAS, FOLFOX/FOLFIRI regimens in combination with the anti-VEGF antibody bevacizumab or with the anti-EGFR antibody cetuximab or panitumumab result in significantly improved clinical efficacy with no worsening of the toxicities normally observed with chemotherapy. In order for patients to derive maximal benefit, they should be treated with each of these active agents in a continuum of care approach. Regorafenib and TAS102 are approved for the chemo-refractory disease setting, but unfortunately, each drug is associated with significant toxicities and only limited clinical efficacy with very low overall response rates; median progression-free survival is about 2-months. Given all of the available treatment regimens, median overall survival for metastatic CRC is now in the 28to 30-month range and, in some cases, approaches or even exceeds 3 years."
        },
        {
            "id": "InternalMed_Harrison_7035",
            "title": "InternalMed_Harrison",
            "content": "both cetuximab and panitumumab can lead to an acne-like rash, with the development and severity of the rash being correlated with the likelihood of antitumor efficacy. Inhibitors of the EGFR tyrosine kinase such as erlotinib (Tarceva) or sunitinib (Sutent) do not appear to be effective in colorectal cancer."
        },
        {
            "id": "Pharmacology_Katzung_5978",
            "title": "Pharmacology_Katzung",
            "content": "Panitumumab is a fully human monoclonal antibody directed against the EGFR and works through inhibition of the EGFR signaling pathway. In contrast to cetuximab, this antibody is of the G2 isotype and, as such, would not be expected to exert any immunologic-mediated effects. Panitumumab was originally approved for patients with refractory metastatic CRC who have been treated with all other active agents. However, it is now also approved for use in combination with FOLFOX chemotherapy in the front-line treatment of metastatic CRC. As with cetuximab, this antibody is only effective in patients whose tumors express wild-type RAS. Recent clinical studies have shown that this antibody can also be effectively and safely combined with irinotecanbased chemotherapy in the second-line treatment of metastatic CRC. Acneiform skin rash and hypomagnesemia are the two main adverse effects associated with its use. Despite being a fully human antibody, infusion-related reactions can still be observed,"
        },
        {
            "id": "InternalMed_Harrison_6951",
            "title": "InternalMed_Harrison",
            "content": "The administration of combinations of cytotoxic drugs to patients with advanced gastric carcinoma has been associated with partial responses in 30\u201350% of cases; responders appear to benefit from treatment. Such drug combinations have generally included cisplatin combined with epirubicin or docetaxel and infusional 5-FU or capecitabine, or with irinotecan. Despite the encouraging response rates, complete remissions are uncommon, the partial responses are transient, and the overall impact of multidrug therapy on survival has been limited; the median survival time for patients treated in this manner remains less than 12 months. As with adenocarcinomas arising in the esophagus, the addition of bevacizumab (Avastin) to chemotherapy regimens in treating gastric cancer appears to provide limited benefit. However, preliminary results utilizing another antiangiogenic compound\u2014ramucirumab (Cyranza)\u2014in the treatment of gastric cancer are encouraging. The use of adjuvant chemotherapy alone"
        },
        {
            "id": "InternalMed_Harrison_7030",
            "title": "InternalMed_Harrison",
            "content": "Systemic therapy for patients with colorectal cancer has become more effective. 5-FU remains the backbone of treatment for this disease. Partial responses are obtained in 15\u201320% of patients. The probability of tumor response appears to be somewhat greater for patients with liver metastases when chemotherapy is infused directly into the hepatic artery, but intraarterial treatment is costly and toxic and does not appear to appreciably prolong survival. The concomitant administration of folinic acid (leucovorin) improves the efficacy of 5-FU in patients with advanced colorectal cancer, presumably by enhancing the binding of 5-FU to its target enzyme, thymidylate synthase. A threefold improvement in the partial response rate is noted when folinic acid is combined with 5-FU; however, the effect on survival is marginal, and the optimal dose schedule remains to be defined. 5-FU is generally administered intravenously but may also be given orally in the form of capecitabine (Xeloda) with"
        },
        {
            "id": "InternalMed_Harrison_6805",
            "title": "InternalMed_Harrison",
            "content": "Agents That Inhibit Angiogenesis Bevacizumab, a monoclonal antibody directed against VEGF, was the first antiangiogenic agent approved for the treatment of patients with advanced NSCLC in the United States. This drug primarily acts by blocking the growth of new blood vessels, which are required for tumor viability. Two randomized phase III trials of chemotherapy with or without bevacizumab had conflicting results. The first trial, conducted in North America, compared carboplatin plus paclitaxel with or without bevacizumab in patients with recurrent or advanced nonsquamous NSCLC and reported a significant improvement in response rate, progression-free survival, and overall survival in patients treated with chemotherapy plus bevacizumab versus chemotherapy alone. Bevacizumab-treated patients had a significantly higher incidence of toxicities. The second trial, conducted in Europe, compared cisplatin/gemcitabine with or without bevacizumab in patients with recurrent or advanced"
        },
        {
            "id": "InternalMed_Harrison_406",
            "title": "InternalMed_Harrison",
            "content": "Tumor and Infectious Agent genomes The actions of drugs used to treat infectious or neoplastic disease may be modulated by variants in these nonhuman germline genomes. Genotyping tumors is a rapidly evolving approach to target therapies to underlying mechanisms and to avoid potentially toxic therapy in patients who would derive no benefit (Chap. 101e). Trastuzumab, which potentiates anthracycline-related cardiotoxicity, is ineffective in breast cancers that do not express the herceptin receptor. Imatinib targets a specific tyrosine kinase, BCR-Abl1, that is generated by the translocation that creates the Philadelphia chromosome typical of chronic myelogenous leukemia (CML). BCR-Abl1 is not only active but may be central to the pathogenesis of CML; its use in BCR-Abl1-positive tumors has resulted in remarkable antitumor efficacy. Similarly, the anti\u2013epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab appear especially effective in colon cancers in which K-ras,"
        },
        {
            "id": "InternalMed_Harrison_7160",
            "title": "InternalMed_Harrison",
            "content": "Survival Study Comparator Arm No. of Patients PFS/DFS (months) Median Survival (months) ESPAC-1, Neoptolemos et al: N Engl J Chemotherapy (folinic acid 289 PFS 15.3 vs 9.4. (p = .02) 20.1 vs 15.5 (HR 0.71; 95% CI Med 350:1200, 2004 + bolus 5-FU) vs no 0.55\u20130.92; p = .009) chemotherapy CONKO 001, Oettle et al: JAMA Gemcitabine vs observation 368 Median DFS 13.4 vs 6.9 22.1 vs 20.2 (p = .06) 297:267, 2007 (p <.001) ESPAC-3, Neoptolemos et al: JAMA 5-FU/LV vs gemcitabine 1088 23 vs 23.6 (HR 0.94; 95% CI 0.81\u20131.08, 304:1073, 2010 p = .39) Abbreviations: CI, confidence interval; CONKO, Charit\u00e9 Onkologie; DFS, disease-free survival; ESPAC, European Study Group for Pancreatic Cancer; 5-FU, 5-fluorouracil; HR, hazard ratio; LV, leucovorin; PFS, progression-free survival. Survival Study Comparator Arm No. of Patients PFS (months) Median Survival (months) Moore et al: J Clin Oncol 26:1960, Gemcitabine vs gemcitabine 569 2007 + erlotinib"
        },
        {
            "id": "Surgery_Schwartz_9436",
            "title": "Surgery_Schwartz",
            "content": "2:44 PM 1425GALLBLADDER AND THE EXTRAHEPATIC BILIARY SYSTEMCHAPTER 32has been found to prolong survival and improve quality of life in patients with biliary stents.95,96Prognosis. Most patients with perihilar cholangiocarcinoma present with advanced, unresectable disease. Median survival in this population is between 5 and 8 months. The most common causes of death are hepatic failure and cholangitis. The overall 5-year survival rate for patients with resectable perihilar cholan-giocarcinoma is between 10% and 30%, but for patients with neg-ative margins, it may be as high as 40%. The operative mortality for perihilar cholangiocarcinoma is 6% to 8%. Patients with distal cholangiocarcinoma are more likely to have resectable disease and improved prognosis compared to perihilar cholangiocarci-noma. The overall 5-year survival rate for resectable distal dis-ease is 30% to 50%, and the median survival is 32 to 38 months. Patients who receive liver transplantation for cholangiocarcinoma"
        },
        {
            "id": "InternalMed_Harrison_7129",
            "title": "InternalMed_Harrison",
            "content": "have been assessed for activity and survival in unresectable CCC. Most have been inactive. However, both systemic and hepatic arterial gemcitabine have shown promising results. The combination of cisplatin plus gemcitabine has produced a survival advantage compared with gemcitabine alone in a 410-patient randomized controlled phase III trial for patients with locally advanced or metastatic CCC and is now considered standard therapy for unresectable CCC. Median overall survival in the combination arm was 11.7 months versus 8.1 months for gemcitabine alone. Significant responses were seen mainly in patients with IHC and gallbladder cancer. However, neither surgery for lymph node\u2013positive disease nor regional chemotherapy in nonsurgical patients has shown any survival advantage thus far. Several case series have shown safety and some responses for hepatic arterial chemotherapy with gemcitabine, drug-eluting beads, and 90Yttrium microspheres, but no convincing clinical trials are"
        },
        {
            "id": "Surgery_Schwartz_9435",
            "title": "Surgery_Schwartz",
            "content": "has been reported with some encouraging results. However, no randomized, prospective trials have been reported.91 Photodynamic therapy has been proposed as a palliative measure for patients with unresectable disease and ABFigure 32-32. A. An endoscopic retrograde cholangiogram in a patient with cancer of the common hepatic duct (arrowheads). The common bile duct is of normal size, as is the cystic duct (arrow), but the proximal biliary tree is dilated. The gallbladder is not visualized because of tumor obstructing its neck. B. An ultrasound from the same patient showing dilated ducts and tumor obstructing the common hepatic duct (arrow). The walls of the bile ducts adjacent to the obstruction are thickened by tumor infiltration (arrowheads).Brunicardi_Ch32_p1393-p1428.indd 142411/02/19 2:44 PM 1425GALLBLADDER AND THE EXTRAHEPATIC BILIARY SYSTEMCHAPTER 32has been found to prolong survival and improve quality of life in patients with biliary stents.95,96Prognosis. Most patients"
        },
        {
            "id": "InternalMed_Harrison_7162",
            "title": "InternalMed_Harrison",
            "content": "Conroy et al: N Engl J Med Gemcitabine vs FOLFIRINOX 342 364:1817, 2011 Onkologie trial (CONKO 001) found that the use of gemcitabine after complete resection significantly delayed the development of recurrent disease compared with surgery alone. The European Study Group for Pancreatic Cancer 3 (ESPAC-3) trial, which investigated the benefit of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine, revealed no survival difference between the two drugs. However, the toxicity profile of adjuvant gemcitabine was superior to 5-FU/FA by virtue of its lower incidence of stomatitis and diarrhea. Adjuvant radiotherapy is not commonly used in Europe based on the negative results of the ESPAC-1 study. Adjuvant 5-FU-based CRT with gemcitabine before and after radiotherapy as used in the Radiation Therapy Oncology Group (RTOG) 97-04 trial is preferred in the United States. This approach may be most beneficial in patients with bulky tumors involving the pancreatic head."
        },
        {
            "id": "InternalMed_Harrison_27124",
            "title": "InternalMed_Harrison",
            "content": "tyrosine kinase receptors (TKRs) and of the mammalian target of rapamycin (mTOR) signaling pathway have been reported to be effective in treating pancreatic NETs and in doubling the progression-free survival time."
        },
        {
            "id": "InternalMed_Harrison_7161",
            "title": "InternalMed_Harrison",
            "content": "Survival Study Comparator Arm No. of Patients PFS (months) Median Survival (months) Moore et al: J Clin Oncol 26:1960, Gemcitabine vs gemcitabine 569 2007 + erlotinib Cunningham et al: J Clin Oncol Gemcitabine vs gemcitabine 533 27:5513, 2009 + capecitabine (GEM-CAP) Von Hoff et al: N Engl J Med Gemcitabine vs gemcitabine 861 369:1691, 2013 + nab-paclitaxel Conroy et al: N Engl J Med Gemcitabine vs FOLFIRINOX 342 364:1817, 2011"
        },
        {
            "id": "InternalMed_Harrison_7126",
            "title": "InternalMed_Harrison",
            "content": "resonance cholangiopancreatography (MRCP) or helical CT scans. Invasive cholangiopancreatography (ERCP) is then needed to define the biliary tree and obtain a biopsy or is needed therapeutically to decompress an obstructed biliary tree with internal stent placement. If that fails, then percutaneous biliary drainage will be needed, with the biliary drainage flowing into an external bag. Central tumors often invade the porta hepatis, and locoregional lymph node involvement by tumor is frequent. Incidence has been increasing in recent decades; few patients survive 5 years. The usual treatment is surgical, but combination systemic chemotherapy may be effective. After complete surgical resection for IHC, 5-year survival is 25\u201330%. Combination radiation therapy with liver transplant has produced a 5-year recurrence-free survival rate of 65%."
        },
        {
            "id": "Surgery_Schwartz_9862",
            "title": "Surgery_Schwartz",
            "content": "can also occur due to digestion of retroperitoneal blood vessels due to a combined biliary-pancreatic leak. Uncom-monly, a stress ulcer, or later, a marginal ulcer, can result in GI hemorrhage. Typically, a vagotomy is not performed when pan-creaticoduodenectomy is performed for pancreatic cancer, but patients are placed on proton pump inhibitors.Outcome and Value of Pancreaticoduodenectomy for Cancer. Survival figures indicate that perhaps few patients are cured indefinitely of pancreatic cancer with pancreaticoduode-nectomy. This has led to a nihilistic view toward patients with this disease which has further contributed to poor outcomes. Using the National Cancer Data Base (1995\u20132004), Bilimoria reported on 9559 patients with early stage potentially resect-able tumors (pretreatment clinical Stage I: T1N0M0 and T2N0M0).364 Multivariate models were employed to identify factors predicting failure to undergo surgery and assess the impact of pancreatectomy on survival. This study"
        },
        {
            "id": "Pharmacology_Katzung_6029",
            "title": "Pharmacology_Katzung",
            "content": "trastuzumab to cisplatin-containing chemotherapy regimens provides significant clinical benefit in metastatic gastric cancer patients whose tumors overexpress the HER-2/neu receptor. At present, the optimal fluoropyrimidine backbone has not been established, and either infused 5-FU or oral capecitabine can be combined with cisplatin plus trastuzumab. For second-line therapy, the combination of ramucirumab plus paclitaxel is recommended for patients with a good performance status and favorable comorbidity profile. In patients who are unable to tolerate more intensive therapy, single-agent ramucirumab or paclitaxel monotherapy are more appropriate treatment options."
        },
        {
            "id": "Pharmacology_Katzung_5976",
            "title": "Pharmacology_Katzung",
            "content": "Cetuximab is a chimeric monoclonal antibody directed against the extracellular domain of the EGFR, and it is presently approved for use in combination with irinotecan for metastatic colon cancer in the refractory setting or as monotherapy in patients who are deemed to be irinotecan-refractory. Because cetuximab is of the G1 isotype, its antitumor activity may also be mediated, in part, by immunologic-mediated mechanisms. There is growing evidence that cetuximab can be effectively and safely combined with irinotecanand oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer as well. Of note, the efficacy of cetuximab is restricted to only those patients whose tumors express the wild-type RAS gene, which includes both KRAS and NRAS. Combination regimens of cetuximab with cytotoxic chemotherapy may be of particular benefit in the neoadjuvant therapy of patients with liver-limited disease. Although this antibody was initially approved to be administered"
        },
        {
            "id": "InternalMed_Harrison_7104",
            "title": "InternalMed_Harrison",
            "content": "to TACE. A major problem that TACE trials have had in showing a survival advantage is that many HCC patients die of their underlying cirrhosis, not the tumor. Nevertheless, two randomized controlled trials, one using doxorubicin and the other using cisplatin, showed a survival advantage for TACE versus placebo (Table 111-6). However, improving quality of life is a legitimate goal of regional therapy. Drug-eluting beads using doxorubicin (DEB-TACE) have been claimed to produce equivalent survival with less toxicity, but this strategy has not been tested in a randomized trial."
        },
        {
            "id": "Surgery_Schwartz_9870",
            "title": "Surgery_Schwartz",
            "content": "in early stage pan-creas cancer. Survival comparison for cases (combined stages IA and IB) for which resection was recommended, and resection was either performed or refused. (Reproduced with permission from Chiari ST, Kelly K, Hollingsworth MA, et al. Early detection of sporadic pancreatic cancer: summative review, Pancreas. 2015 Jul;44(5):693-712.)Brunicardi_Ch33_p1429-p1516.indd 149801/03/19 6:46 PM 1499PANCREASCHAPTER 33clinical trials of neoadjuvant therapy for resectable pancreatic cancer.368 Unfortunately, a recent trial attempting to random-ize patients with resectable pancreatic cancer to neoadjuvant versus adjuvant therapy failed to demonstrate an advantage for the neoadjuvant approach. However, the study was inconclu-sive because it was stopped after 73 of a planned 254 patients due to slow accrual, with only 66 eligible for analysis. Other trials are ongoing. The NEOPA trial (ClinicalTrials.gov iden-tifier: NCT01900327) is a prospectively randomized phase 3 trial of"
        }
    ],
    "scores": [
        0.030430856096917803,
        0.029248521406769378,
        0.027911123963755544,
        0.026671176434413628,
        0.026299604666652345,
        0.026248677499328882,
        0.025501114538893928,
        0.025322827407564242,
        0.025126195169580513,
        0.024180415147757026,
        0.02355907003794328,
        0.023177970973326842,
        0.022326882647334248,
        0.021949085819263407,
        0.02153569086750126,
        0.02149329241180362,
        0.02125785179972372,
        0.019172816635991758,
        0.019137190201389997,
        0.01906318082788671,
        0.018558295386201563,
        0.017980970811159493,
        0.01786843769765971,
        0.017582753612109165,
        0.017523722069176614,
        0.016880341880341883,
        0.016476215785277703,
        0.016108164057445983,
        0.01597703301504088,
        0.015453639082751745,
        0.015287356321839082,
        0.015262954155836974
    ]
}